As of September 30, 2026, Janux Therapeutics, Inc. carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 131.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.06B |
| Enterprise Value | 131.76M |
Janux Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 5, 2027.
| Earnings Date | 3/5/2027 |
As of September 30, 2026, Janux Therapeutics, Inc. has 61.17M shares outstanding.
| Shares Outstanding | 61.17M |
These figures are as of September 30, 2026. The price-to-sales ratio is 46.53, and the price-to-book ratio stands at 1.16.
| PS Ratio | 46.53 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | -20.01 |
| P/OCF Ratio | -20.23 |
These figures are as of September 30, 2026. The EV/Sales ratio of 5.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 131.76M versus a market cap of 1.06B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 5.66 |
As of September 30, 2026, Janux Therapeutics, Inc. maintains a current ratio of 17.69, meaning it holds 17.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.69 |
| Quick Ratio | 17.56 |
| Debt / Equity | 2.24 |
| Debt / EBITDA | -0.15 |
Over the twelve months ended September 30, 2026, Janux Therapeutics, Inc. posted a negative return on equity (ROE) of -10.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.94, reflecting losses generated across the asset base. The company generates approximately 213,660.55 in revenue per employee across its workforce of 109.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -10.58 |
| Return on Assets (ROA) | -9.94 |
| Revenue Per Employee | 213,660.55 |
| Employee Count | 109.00 |
As of the close on November 16, 2026, Janux Therapeutics, Inc.'s stock has declined approximately 62.70% over the past 52 weeks. The 50-day moving average sits at 16.61, while the 200-day moving average is 15.34.
| 52-Week Price Change | -62.70% |
| 50-Day Moving Average | 16.61 |
| 200-Day Moving Average | 15.34 |
Over the twelve months ended September 30, 2026, Janux Therapeutics, Inc. generated 23.29M in revenue and converted that into -99.85M in net income, yielding earnings per share of -1.59. EBITDA reached -137.70M, while operating income came in at -139.56M.
| Revenue | 23.29M |
| Operating Income | -139.56M |
| Pretax Income | -99.85M |
| Net Income | -99.85M |
| EBITDA | -137.70M |
| EBIT | -139.56M |
| Earnings Per Share (EPS) | -1.59 |
As of September 30, 2026, Janux Therapeutics, Inc. holds 945.72M in cash and equivalents against 20.38M in total debt, resulting in a net debt position of -41.82M. Total book value stands at 911.61M, with working capital of 905.14M providing operational flexibility.
| Cash & Cash Equivalents | 945.72M |
| Total Debt | 20.38M |
| Net Debt | -41.82M |
| Equity (Book Value) | 911.61M |
| Book Value Per Share | 14.90 |
| Working Capital | 905.14M |
Janux Therapeutics, Inc. produced -53.58M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -583,000.00 in capital expenditures, free cash flow totaled -54.16M - equivalent to -0.86 per share.
| Operating Cash Flow | -53.58M |
| Capital Expenditures | -583,000.00 |
| Free Cash Flow | -54.16M |
| FCF Per Share | -0.86 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -599.26 and net profit margin of -428.74 provide insight into operational efficiency.
| Operating Margin | -599.26 |
| Pretax Margin | -428.74 |
| Profit Margin | -428.74 |
| EBITDA Margin | -591.28 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -5.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.91, meaning Janux Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.91 |
| FCF Yield | -5.00 |
As of September 30, 2026, Janux Therapeutics, Inc. has an Altman Z-Score of 8.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.87 |